<DOC>
	<DOCNO>NCT02452931</DOCNO>
	<brief_summary>This study determine effectiveness leuprolide acetate 45 mg injectable suspension treatment child Central Precocious Puberty .</brief_summary>
	<brief_title>Pharmacokinetic Study Leuprolide Acetate Injectable Suspension Treatment Central Precocious Puberty</brief_title>
	<detailed_description>Leuprolide acetate GnRH agonist inhibits pituitary gonadotropin secretion bind GnRH receptor block downstream hormone synthesis . The steady decrease hormone synthesis ( LH FSH ) lead suppression testicular ovarian steroidogenesis . In child CPP , steady decrease hormone synthesis disrupts progression puberty .</detailed_description>
	<mesh_term>Puberty , Precocious</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Females age 2 8 year ( inclusive ) male age 2 9 year ( inclusive ) Confirmed diagnosis CPP within 12 month Baseline Visit ( Day 0 ) receive prior GnRH agonist treatment CPP Pubertaltype LH response follow abbreviated GnRHa stimulation test treatment initiation Clinical evidence puberty , define Tanner stage ≥ 2 breast development female testicular volume ≥ 4 mL male Difference bone age ( Greulich Pyle method ) chronological age ≥ 1 year Gonadotropinindependent ( peripheral ) precocious puberty Prior current GnRH treatment CPP Prior current therapy medroxyprogesterone acetate , growth hormone insulinlike growth factor1 ( IGF1 ) Diagnosis short stature ( ie , 2.25 standard deviation ( SD ) mean height age ) Known history seizure , epilepsy , and/or central nervous system disorder may associate seizure convulsion Any medical condition serious intercurrent illness , opinion Investigator , may make undesirable subject participate study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>